Chargement de votre page…
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Par Kong L, Li P, Bi Y et 4 autres.
Contenu en anglais
Ward réunit ces articles dans la même app que vos cartes et vos questions. Un seul compte gratuit pour Ward, Suture, Osler et Prognia.
Freezing of gait (FoG) and axial impairments often persist in Parkinson's disease despite optimized medication and subthalamic nucleus deep brain stimulation (STN-DBS). We systematically reviewed whether adding substantia nigra pars reticulata (SNr) stimulation improves motor and FoG outcomes.
Following PRISMA 2020 and PROSPERO registration (CRD420261343479), six databases were searched through 1 May 2026. Primary outcomes compared STN-SNr co-stimulation with STN-only stimulation; stimulation-off or baseline comparisons were secondary. Two reviewers independently screened studies, extracted data, and assessed risk of bias. UPDRS-III and FoG were pooled as mean differences (MDs) and Hedges' g, respectively, accounting for paired data and within-study dependence. Certainty was assessed using GRADE.
Ten studies (nine randomized trials and one observational study) included 109 unique evaluable participants; two single-patient case reports were summarized narratively. UPDRS-III showed no between-group difference across seven studies (73 participants; MD - 0.10, 95% CI - 1.01 to 0.81; I² = 0%; low certainty). FoG showed no additional benefit across six studies (86 participants; Hedges' g - 0.23, 95% CI - 1.04 to 0.59; I²_total = 85.6%; very low certainty). Secondary baseline comparisons favored co-stimulation for UPDRS-III (MD - 13.55) and FoG (Hedges' g - 0.60), but did not isolate an incremental SNr effect.
Low-certainty evidence suggests no clinically important difference in global motor outcomes, while very-low-certainty evidence does not demonstrate a consistent additional FoG benefit. Improvements versus stimulation-off or baseline cannot establish an incremental SNr effect. Larger phenotype-stratified trials with objective gait endpoints and systematic adverse-event reporting are needed.
Publié dans Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. Le résumé est reproduit tel qu’il a été publié et reste l’œuvre de ses auteurs ; lisez l’article complet à la source.
Prognia référence cet article à des fins de documentation et de formation. Il ne constitue pas un avis médical. Lisez toujours l’original et suivez les recommandations en vigueur et les protocoles locaux avant d’agir.
